Scotiabank analyst Greg Harrison raised the firm’s price target on Travere Therapeutics (TVTX) to $32 from $27 and keeps an Outperform rating on the shares. The company recently announced plans to file a supplemental new drug application for Filspari and, while approval is not guaranteed, the firm suspects an sNDA submission would not have been suggested if the FDA was not open to considering an approval.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics price target raised to $45 from $22 at Canaccord
- Coca-Cola reports Q4 beat, Elliott discloses Phillips 66 stake: Morning Buzz
- Wells bullish on Travere Therapeutics, sees 30% of upside on submission plans
- Travere Therapeutics to submit sNDA for FILSPARI in FSGS
- Promising Outlook for Travere Therapeutics Driven by Filspari’s Market Potential and Financial Strength